Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
MedChem Buzz
Kilomentor
On Pharma
A New Merck, Reviewed
Liberal Arts Chemistry
One in Ten Thousand
Electron Pusher
Periodic Tabloid
All Things Metathesis
C&E News Blog
Propter Doc
Chemiotics II
The Chemical Notebook
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
Chirality
BBSRC/Douglas Kell
ChemBark
Drug Discovery Opinion
Realizations in Biostatistics
Chemjobber
Pharmalot
WSJ Health Blog
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Useful Chemistry
Chiral Jones
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Totally Synthetic
Fragment Literature
The F- Blog
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Carbon-Based Curiosities
Experimental Error
Business|Bytes|Genes|Molecules
Eye on FDA
Sigma-Aldrich ChemBlogs
Chemical Forums
Depth-First
Symyx Blog
P212121
ChemCafe
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
A Scientist's Life
Speculist
Cosmic Variance
The Capsule
Zeroth Order Approximation
Biology News Net


Medical Blogs
Med Tech Sentinel
DB's Medical Rants
Science-Based Medicine
GruntDoc
The Health Care Blog
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Megan McArdle
Mickey Kaus
Colby Cosh
Alien Corn
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« How Drugs Die | Main | One Of Us Is Hallucinating »

February 19, 2004

All Fixed Up

Email This Entry

Posted by Derek

Time to revisit a long-standing topic. You may well have noticed the news items about the FDA's new programs to crack down on prescription drug counterfeiting. That sort of crime is to be expected, given the money to be made - although you really have to wonder about the human status of anyone who turns out fake medicines, full of confectioner's sugar or whatnot. It would be more honest and aboveboard to sneak into someone's hospital room and dig through whatever purses or wallets you could find. Less damaging to the victim, too, for that matter.


So any cost-effective means to cut down on this is welcome. But does a bluff make a sound when it's being called? Regular readers will know that I've spoken out several times about drug reimportation from Canada, and how I oppose it on economic grounds. But my industry's trade association, PhRMA, has taken their stand on the drug safety part of the issue. "Don't import those contaminated drugs!" goes the cry. (How many of the counterfeits seized to date actually came through Canadian pharmacies, I wonder?)


As I've said, one problem with this line of attack is that it doesn't get at the real heart of the issue, which is the cost of research and the money that needs to be made to fund it. (And yes, I know, the costs of marketing, too - but keep in mind that companies, in whatever industry, don't spend that kind of marketing money year after year without getting a good return on it as well. We can debate how much advertising drug companies should be allowed to do, but don't assume that we're throwing the money out the window.) There will be more next week on drug costs and research spending (the mail keeps on coming!), but no matter what, I think we can assume that the two are somehow related.


No, the real problem with the drug-safety argument is that it makes reimportation seem like an otherwise harmless thing, that just suffers from this unfortunate side problem. What happens if someone actually fixes it? What's my industry going to be able to say then? There is a backup plan, right, guys?

Comments (0) + TrackBacks (0) | Category:


COMMENTS

EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Academia and Industry, Suing Each Other
Let's Start Off the Meeting With An Ad, OK?
The Academic-Industrial Collaboration in Drug Discovery Panel: Today
Glass Structure, Atom by Atom
How the Andrulis Paper Got Published
AstraZeneca in Waltham
Fluorine NMR: Why Not?
AstraZeneca Layoffs and Closings